SCHEMBL30296352

SCHEMBL30296352

C=CCC[C@@H](Nc1ccc(OC)cc1)c1ccnc(OC(F)F)c1Br

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPT P10636 6/20 0.33
HTT P42858 1/20 0.33
KDM4E B2RXH2 3/20 0.32
MAPK1 P28482 2/20 0.32
POLB P06746 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ROCK1 Q13464 1/20 0.32
LMNA P02545 2/20 0.31
ALOX12 P18054 1/20 0.31
NPC1 O15118 3/20 0.31
GALR2 O43603 1/20 0.31
GALR1 P47211 1/20 0.31
GAA P10253 1/20 0.31
GRK6 P43250 1/20 0.31
CCNA2 P20248 1/20 0.30
CDK2 P24941 1/20 0.30
CCNA1 P78396 1/20 0.30
PPARG P37231 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30296575 0.79 CYP3A4 (0.35) MEN1KMT2AMAPTKDM4EMAPK1
SCHEMBL30391197 0.78 L3MBTL1 (0.40) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL26880317 0.78 L3MBTL1 (0.40) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL30296265 0.78 MAPT (0.37) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL24571289 0.78 MEN1 (0.36) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL30296604 0.78 MEN1 (0.36) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL26093317 0.78 MEN1 (0.36) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL26880632 0.78 MEN1 (0.36) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL26880325 0.77 GRK6 (0.39) MEN1KMT2AMAPTHTTKDM4E
SCHEMBL26880237 0.77 KMT2A (0.41) MEN1KMT2AMAPTHTTKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-11-07 US disclosed
EP-4419203-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2024-08-28 EP disclosed
CN-118451080-A Tricyclic GPR65 modulators 帕蒂奥斯治疗有限公司 2024-08-06 CN disclosed
WO-2023067322-A1 TRICYCLIC GPR65 MODULATORS Pathios Therapeutics Limited (GB) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240368173-A1 TRICYCLIC GPR65 MODULATORS GPR65, GPR3, NR1H2 MEN1 4599/4885KMT2A 3316/4885MAPT 4580/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.